Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tozasertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-05 |
| Autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor | Withdrawn | Phase 3 | 6 | 3 | 5 | 30 | 1 | EU | — | 1999-11 |
| Vindesine | Withdrawn | Phase 4 | 5 | 4 | 20 | 36 | 1 | CA | — | 1990-07 |
| Bacillus Calmette-Guerin BCG | Withdrawn | Phase 4 | 4 | 0 | 3 | 9 | 1 | CA | — | 2009-09 |
| Peginterferon Alfa-2b | Withdrawn | Phase 4 | 3 | 1 | 8 | 50 | 17 | CA | — | Dec 29, 1997 |
| Necitumumab | Withdrawn | Phase 3 | 3 | 0 | 2 | 21 | 2 | CA, EU | — | 2004-11 |
| Teniposide | Withdrawn | Phase 4 | 3 | 3 | 1 | 14 | 1 | CA | — | 1993-01 |
| Interferon Alfa-2b | Withdrawn | Phase 4 | 1 | 0 | 5 | 23 | 16 | CA, EU | — | Aug 5, 1998 |
| Amsacrine | Withdrawn | Phase 3 | 1 | 1 | 6 | 8 | 1 | CA | — | 1986-11 |
| Moxetumomab Pasudotox | Withdrawn | Phase 3 | 1 | 0 | 1 | 7 | 1 | EU | — | May 10, 2007 |
| Streptozocin | Withdrawn | Phase 3 | 1 | 0 | 1 | 7 | 1 | CA | — | 1996-08 |
| Yttrium-90 | Withdrawn | Phase 1 | 1 | 0 | 0 | 1 | 1 | CA | — | Sep 16, 2020 |
| Estramustine | Withdrawn | Phase 3 | 0 | 0 | 7 | 48 | 2 | CA | — | 1995-03 |
| Infigratinib | Withdrawn | Phase 3 | 0 | 0 | 2 | 24 | 4 | CA | — | Dec 11, 2009 |
| Olaratumab | Withdrawn | Phase 3 | 0 | 0 | 1 | 19 | 3 | CA, EU | — | 2006-12 |
| Interferon Alpha-2a | Withdrawn | Phase 3 | 0 | 0 | 2 | 4 | 12 | CA | — | 1994-09 |
| Pixantrone Dimaleate | Withdrawn | Phase 3 | 0 | 0 | 1 | 4 | 1 | EU | — | 2002-02 |
| Tositumomab | Withdrawn | Phase 2 | 0 | 0 | 0 | 3 | 1 | CA | — | 2004-04 |
| Interferon Alfacon-1 | Withdrawn | Phase 1 | 0 | 0 | 0 | 2 | 1 | CA | — | 2013-07 |
| Altretamine | Withdrawn | Phase 1 | 0 | 0 | 0 | 1 | 1 | CA | — | 1996-07 |
| Aminoglutethimide | Withdrawn | Phase 2 | 0 | 0 | 0 | 1 | 1 | CA | — | 2000-05 |
| Diethylstilbestrol | Withdrawn | Phase 3 | 0 | 0 | 1 | 1 | 7 | CA | — | 2002-12 |
| Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) | Withdrawn | — | 0 | 0 | 0 | 0 | 1 | EU | — | — |
| Bacillus Calmette-Guerin (bcg) Substrain Connaught | Withdrawn | — | 0 | 0 | 0 | 0 | 1 | CA | — | — |
| Bacillus Calmette-Guerin (bcg) Substrain Montreal | Withdrawn | — | 0 | 0 | 0 | 0 | 1 | CA | — | — |
| Interferon Alpha-N1 | Withdrawn | — | 0 | 0 | 0 | 0 | 2 | CA | — | — |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.